Clinical Trial

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, first-in-human study to evaluate the safety,efficacy, and PK/PD characteristics of SIM0508 as a single agent and in combination with olaparib in participants with locally advanced/metastatic solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-12.
Status change: Not Yet Recruiting → Recruiting 2025-01-06
Trial Details
NCT Number NCT06686745
Lead Sponsor Jiangsu Simcere Pharmaceutical Co., Ltd.
Collaborators: Shanghai Xianxiang Medical Technology Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 130 participants
Start Date 2024-12-06
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-07